You are here: Home » Archives for 2025

Bitget Opens Access for AI Agent-Assisted Trading Boosting Wider Crypto Adoption

VICTORIA, Seychelles, Aug. 19, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced its AI–powered trading assistant, GetAgent, is now available to all users. First introduced in July in an invite–only launch, GetAgent blends advanced AI with real–time market data to deliver insights, strategies, and execution tools in one seamless chat interface.

During the invite–only period, GetAgent received great feedback, amassing a waitlist of over 25,000 users. Early adopters provided valuable suggestions, including the need for more visual feedback to make market signals easier to interpret. These insights have helped sharpen the platform’s accuracy, personalization, and responsiveness ahead of today’s public launch.

With the public launch, GetAgent is introducing three membership tiers to meet the needs of different types of traders. The Free plan is open to everyone and offers analysis of the top 50 coins alongside futures strategies. The Plus plan, available with a free 30–day trial for early access users, includes up to ten daily questions, personalized strategy generation, and deeper market analysis. For high–frequency and professional traders, the Ultra plan offers priority access, up to fifty daily questions, and early access to upcoming features. These tiers are designed to scale with users’ trading ambitions, delivering smarter trades, sharper insights, and AI–powered automation for portfolios, trading signals, and market moves.

To celebrate the public release, Bitget is launching a limited–time GetAgent Experience–Sharing Campaign. All users can participate for a chance to win a free 30–day GetAgent Plus membership by sharing their experiences with the assistant.

With its public debut, GetAgent now lets traders generate strategies in plain language, cutting through complexity with a simple prompt. It bundles over 50 pro–grade tools—spanning market insights, on–chain data, and social sentiment—into one AI–powered hub. Smarter with every use, the assistant adapts to each trader’s style, serving up sharper strategies and timely risk alerts in real time.

“AI is changing the trading game, and GetAgent is our way of making that power accessible to everyone,” said Gracy Chen, CEO of Bitget. “Whether you’re just starting in crypto or a seasoned market veteran, GetAgent delivers insights that help you move faster, trade smarter, and act with greater confidence.”

Bitget will continue to upgrade GetAgent with expanded integrations, additional asset coverage, and more customization options, ensuring it evolves alongside the market and its users.

GetAgent is the latest addition to Bitget’s growing suite of AI–enabled tools, which also includes Bitget Seed, an AI–powered platform for discovering early–stage Web3 projects. Both align with Bitget’s mission to integrate emerging technologies like AI into its secure CeDeFi trading ecosystem, bridging on–chain innovation with user–friendly tools that empower everyday traders.

About Bitget

Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real–time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Bitget Wallet is a leading non–custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi–chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7b59791–38fe–4e9f–826f–d062be5407ca


GLOBENEWSWIRE (Distribution ID 1001123547)

UN Report Uncovers “Systematic Torture” in Myanmar

Nang, 28, a mother of three, is pictured with her son, Tun Lin, at their home in Namsang Township, Shan State. Credit: UNICEF/Nyan Zay Htet

By Oritro Karim
UNITED NATIONS, Aug 19 2025 – Myanmar’s security situation has deteriorated significantly, with the nation still reeling from the devastating earthquake in March last year, and continued military offensives driven by the ongoing civil war. In 2025, the humanitarian crisis reached a critical turning point, with the United Nations (UN) underscoring a litany of severe human rights abuses inflicted on civilians by the military and armed groups.

On August 12, the Independent Investigative Mechanism for Myanmar (IIMM) released its annual UN-mandated report, stating that it had made significant progress in documenting human rights violations and identifying perpetrators. The report details ongoing atrocities, including the torture of civilians in military-run detention facilities, coordinated aerial strikes on schools, hospitals and homes, and the continued ethnic-cleansing of Rohingya refugees.

“We have uncovered significant evidence, including eyewitness testimony, showing systematic torture in Myanmar detention facilities,” said Nicholas Koumjian, Head of the Mechanism. “We have made headway in identifying the perpetrators, including the commanders who oversee these facilities, and we stand ready to support any jurisdictions willing and able to prosecute these crimes. Our Report highlights a continued increase in the frequency and brutality of atrocities committed in Myanmar.”

The report covers developments in Myanmar from July 1, 2024, to June 30, 2025, drawing on more than 1,300 sources—including 600 eyewitness testimonies, substantial photographic and video evidence, as well as forensic material. Since the 2021 coup, the Myanmar military has detained a large number of civilians, many of whom were arbitrarily arrested on suspicion of opposing the regime, and subjected them to brutal, systematic torture.

According to 2024 figures from the Office of the United Nations High Commissioner for Human Rights (OHCHR), since 2021, there have been approximately 6,000 civilian deaths as a result of violence, including nearly 2,000 civilians who died in military custody. Humanitarian experts have expressed alarm over the military’s use of enforced disappearance, arbitrary arrests, and physical torture to silence opposition.

“Thousands of Myanmar detainees are suffering in silence in interrogation facilities and prisons across the country, where health care, access to legal services, and food are inadequate,” said Joe Freeman, a Myanmar researcher at Amnesty International. “Torture and other ill-treatment in Myanmar detention facilities is common, but few people have a way to lodge complaints or stop the abuse without risking serious retribution, from beatings to solitary confinement to sexual violence.”
Eyewitnesses have described several of these detainees as children, some as young as two years old, with many acting as “proxies” for their parents. Detainees have experienced varying forms of physical torture, such as beatings, electric shocks, strangulations, killings, and even the removal of fingernails with pliers, particularly during the interrogation process.

Numerous detainees have also endured sexual and gender-based violence, including rape—both individual and gang assaults—forced insertion of objects into orifices, burning of sexual body parts with cigarettes or heated objects, forced nudity, invasive body searches, sexualized touching, and denial of access to menstrual hygiene and postnatal care products. Eyewitness accounts also describe detainees being targeted with homophobic and misogynistic slurs, as well as threats of physical violence.

In the report, the Mechanism confirmed that the list of perpetrators include many high-level commanders. Myanmar’s military responded to the international criticism by reaffirming its priorities of ensuring peace and stability while blaming “terrorists” for the recent hostilities.

Additionally, the Mechanism underscores a significant rise in hostilities in the Rakhine State as a result of clashes between the military and the Arakan army ethnic armed group. According to the report, the Mechanism has found evidence linking Arakan army members to a host of human rights abuses targeting the Rakhine, Rohingya, and other civilian communities, including summary executions, beheadings, and torture.

The Mechanism has also linked the military and its affiliated groups to indiscriminate killings of civilians, including women, children, and the elderly. They have also documented incidents of indiscriminate aerial bombardments and shellings in Arakan-controlled areas in Southern and Northern Rakhine. Furthermore, the report states that the military has blocked critical entry points in Sittwe, severely restricting civilian movement and the flow of humanitarian aid and other essential supplies.

During the reporting period, the Mechanism also conducted a thorough investigation of crimes associated with the 2016 and 2017 clearance operations that resulted in the destruction of several Rohingya villages, the displacement of thousands of Rohingya civilians into Bangladesh, and widespread insecurity and gender-based violence in Rakhine State. According to the figures from the United Nations Refugee Agency (UNHCR), recent hostilities have displaced over 150,000 Rohingya refugees to Bangladesh in 2025.

The Mechanism focused on interviewing members of the Rohingya population in displacement shelters and the most violence-affected villages, aiming to “canvass the entirety of a survivor’s experience” and gain more direct, witness-based evidence that links specific individuals to the crimes. Currently, the Mechanism is collaborating with civil society groups, non-governmental organizations, media outlets, and governments to identify perpetrators and end impunity for human rights violations. In an effort to promote ethical investigations, the Mechanism is only providing evidence to local authorities with informed consent from affected communities.

Investigators have warned of continued access challenges due to insecurity, as well as recent UN budget cuts threaten to undermine fact-finding operations. This year’s reduction of UN aid has slashed the Mechanism’s 2025 budget to 73 percent, requiring a 20 percent reduction of regular-budget staff in 2026 in order to continue operations. Koumjian states that funding for witness security and research on sexual violence and crimes against children is projected to run out by the end of the year.

“It’s very important that perpetrators believe that somebody is watching, somebody is collecting evidence,” said Koumjian. “All of this would have a very substantial effect on our ability to continue to document the crimes and provide evidence that will be useful to jurisdictions prosecuting these cases.”

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

UN Staff Federation Remembers with Sorrow the Many who have Fallen in the Line of Duty

Credit: United Nations

 
On August 19, the UN commemorated World Humanitarian Day — a time to honor those who step into crises to help others, and to stand with the millions of people whose lives hang in the balance. This year the message is clear: the humanitarian system is stretched to its limits; underfunded, overwhelmed and under attack.

 
“Where bombs fall and disasters strike, humanitarian workers are the ones holding the line keeping people alive, often at great personal risk. But more and more those who help are becoming targets themselves. In 2024 alone over 380 humanitarian workers were killed. Some in the line of duty, others in their homes. Hundreds more have been injured, kidnapped or detained, and there is reason to fear 2025 could be worse,” warns the UN.

By Nathalie Meynet
GENEVA, Aug 19 2025 – On this World Humanitarian Day, the members of CCISUA Staff Federation honour colleagues who dedicate their lives to protecting people in crisis, and we remember with sorrow the many who have fallen in the line of duty.

This year’s theme, “Act For Humanity” is a call to leaders and to the public to confront the normalization of attacks on civilians, including humanitarians, and the impunity that undermines International Humanitarian Law. It is a call to build public support that pressures parties to conflict and world leaders to act to protect civilians and humanitarian workers.

We pay special tribute to our Palestinian colleagues in Gaza, where more than 300 UN staff have been killed since October 2023, the highest toll in UN history. They continue to serve under unimaginable conditions, often while enduring the same loss, hunger, and insecurity as the communities they assist.

At the same time, the humanitarian space itself is under grave threat. Severe funding cuts are forcing agencies to scale back life-saving programmes and reduce their workforce. Structural reforms and discussions of mergers raise additional fears that humanitarian action may lose its independence, becoming subordinated to political or migration-management agendas. For staff on the ground, this translates into uncertainty, heavier risks, and the erosion of trust.

As the federation representing thousands of UN staff worldwide, including many humanitarians, CCISUA calls for stronger protection of humanitarian workers, accountability for attacks, adequate funding for principled action, and genuine consultation on reforms that affect the future of humanitarian response.

The future of humanitarian action is at stake. To protect it, we must Act For Humanity!

Nathalie Meynet is President CCISUA.

The Coordinating Committee for International Staff Unions and Associations of the United Nations System (CCISUA) is the umbrella federation for over 60,000 staff, comprised of UN common system staff unions and associations committed to an atmosphere of constructive cooperation in order to provide equitable and effective representation of staff at all levels. CCISUA primarily represents member interests in inter-agency bodies that make decisions and recommendations on conditions of service.

https://www.ccisua.org/about-us/

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

In Gaza, “the Most Ordinary Things Can Kill”

Aitor Zabalgogeazkoa during an interview with IPS in Bilbao (Spain). Recently returned from Gaza, this Basque aid worker has spent three decades in the field of humanitarian work. Credit: Andoni Lubaki/IPS

Aitor Zabalgogeazkoa during an interview with IPS in Bilbao (Spain). Recently returned from Gaza, this Basque aid worker has spent three decades in the field of humanitarian work. Credit: Andoni Lubaki/IPS

By Karlos Zurutuza
BILBAO, Spain, Aug 19 2025 – It’s 8am when Nasser Hospital in Gaza opens its doors. Aitor Zabalgogeazkoa, Doctors Without Borders’ emergency coordinator in the besieged territory, has already been at work for more than three hours.

“The first thing is to check online where the explosions or gunfire I heard overnight actually took place. That’s when we start organising the day,” says the 61-year-old MSF staffer, during an interview with IPS in Bilbao —400 kilometres north of Madrid. He has just returned home after two months in Gaza.

“By half past eight, the hospital has already reached its daily capacity. Children, women, the wounded… many are left outside because the system is overwhelmed. It’s incredibly hard to manage,” Zabalgogeazkoa explains.

That has been the reality since October 2023, when Israel launched its military offensive on the Gaza Strip, a Palestinian enclave bordering Egypt but cut off from the West Bank, where most Palestinians live.

 

Gazans living in tents set up on the beach fetch water in jerrycans. Access to even the most basic supplies has become a daily ordeal during the war. Credit: MSF

Gazans living in tents set up on the beach fetch water in jerrycans. Access to even the most basic supplies has become a daily ordeal during the war. Credit: MSF

 

According to Gaza’s health ministry, the campaign has so far left more than 60,000 dead and 145,000 injured. The vast majority are civilians, including thousands of women and children.

Israel argues its operation is aimed at destroying Hamas’s military capacity — the Palestinian militia and governing authority in Gaza — following the 7 October 2023 attack in which around 1,200 people were killed in Israel and more than 240 taken hostage. Fifty remain in captivity, though only about 20 are thought to be alive.

The UN has warned of an “unprecedented humanitarian crisis,” with more than 90% of the population displaced and swathes of the enclave reduced to rubble. Numerous governments, international organisations and UN human rights experts have called it “genocide.”

“It’s two million people trapped between bombs and hunger, in 365 square kilometres where conditions deteriorate by the day,” says Zabalgogeazkoa.

“Other than the war injuries, the most ordinary things can kill”: if you’re diabetic you’ll lose your foot because there’s no insulin; if you’re malnourished you can’t care for your children… Even being coeliac can kill you.”

 

A healthcare worker tends to a newborn in an incubator. The lack of fuel also affects hospitals, which rely on generators for electricity. Credit: MSF

A healthcare worker tends to a newborn in an incubator. The lack of fuel also affects hospitals, which rely on generators for electricity. Credit: MSF

 

“An orchestrated massacre”

The MSF coordinator notes that only two of the four food distribution points run by the Gaza Humanitarian Foundation (GHF) — an organisation backed by the US and Israel but heavily criticised — are still operating.

“Other than the war injuries, the most ordinary things can kill”: if you’re diabetic you’ll lose your foot because there’s no insulin; if you’re malnourished you can’t care for your children… Even being coeliac can kill you.”
“People have to cross war zones to get there, and then chaos breaks out. Many are injured in the stampedes of desperation. In the end, it’s thousands fighting for a few sacks of flour,” he recalls.

A Reporters Without Borders investigation published on 7 August, titled This is not aid, this is an orchestrated massacre, described the centres as “death traps”, called for the programme to be scrapped, demanded the reinstatement of the UN-coordinated mechanism, and urged governments and donors to cut support for GHF.

“Distributions start at nine, but two hours earlier you already hear the gunfire. Israel says there’s no other way to control the crowds, but we come across people with bullets in the head or chest,” explains Zabalgogeazkoa.

Since the offensive began, eight health facilities in Gaza have been targeted by the Israeli army, most of them bombed from the air.

“At Nasser Hospital they killed patients by firing a missile through a window on two occasions. Soldiers also stormed the building and we had to evacuate. We couldn’t return for weeks. It was one of the hospitals where babies were left in incubators, and nothing more was ever heard of them,” he laments.

Fuel shortages to power hospital generators have forced doctors in Gaza to take extreme measures, such as placing several babies in a single incubator. MSF staff have reported cases of up to six infants in one unit.

Even water supply is a major struggle. Zabalgogeazkoa notes that 70% of the urban network is destroyed, so much of the water never reaches its destination.

Israel maintains that Gaza’s hospitals often conceal military targets, including “Hamas command centres” and “tunnel networks.”

The MSF staffer rejects this outright: “They always use the same narrative, also when they kill journalists living in tents set up inside hospitals. For Israel, everyone is Hamas. Were all the journalists they killed Hamas too?”

 

Gaza residents in a district bombed by the Israeli army. After nearly two years of offensive, the territory has been reduced to rubble. Credit: MSF

Gaza residents in a district bombed by the Israeli army. After nearly two years of offensive, the territory has been reduced to rubble. Credit: MSF

 

“Inconvenient witnesses”

The UN reports that at least 242 journalists have been killed in Gaza since the offensive began — the highest number ever recorded in a conflict. The vast majority were Palestinian, as Israel has barred international press access. The few foreign correspondents who entered did so embedded with Israeli troops and were unable to work independently.

Nothing seems to stem the chain of attacks on local journalists, who bear the responsibility of documenting the horror.

On 30 June this year, an Israeli airstrike destroyed the al-Baqa café, killing at least 41 people, among them Palestinian photographer and filmmaker Ismail Abu Hatab. The café had been a popular meeting place for young people, journalists and artists, and one of the few places where residents could access the internet and charge their phones during the war.

On 11 August, four Al Jazeera reporters and a local fixer were killed when a bomb struck al-Shifa Hospital. The head of UNRWA accused Israel of “silencing the voices exposing atrocities in Gaza.”

“They’re killing journalists one by one. Now almost everything is left to 16-year-olds posting videos on social media with their phones,” says Zabalgogeazkoa, describing it as a “systematic elimination of inconvenient witnesses.”

With Hamas’s leadership decimated and no local government to manage resources or administer justice, the Strip is descending into chaos. “Israel is doing everything it can to bring about the complete breakdown of Gazan society,” he warns.

“Besides, medicines, food, fuel… they are manipulated in a cruel game. Just when supplies are about to run out, Israel allows enough for another three or four days. People are so consumed with survival that they cannot think about anything else,” adds the MSF staffer.

He is due to return to Gaza in mid-September, though he fears conditions will have worsened by then.

On 10 August, Israeli prime minister Benjamin Netanyahu announced the approval of a plan for a full takeover of Gaza as “the fastest way to end the war, eliminate Hamas and free the hostages.”

The announcement drew widespread international condemnation. Few doubt the already dire humanitarian situation will deteriorate even further.

 

Nyxoah Reports Second Quarter Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter Financial and Operating Results
FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch

Mont–Saint–Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025.

Recent Financial and Operating Highlights

  • Received U.S. Food and Drug Administration (FDA) Pre–Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the U.S.
  • Kicked off the U.S. commercial launch of the Genio system
  • DREAM pivotal study data published in the Journal of Clinical Sleep Medicine
  • Revenue for the second quarter of 2025 was €1.3 million, compared to €0.8 million in the second quarter of 2024, representing 74% year over year growth
  • Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, compared to €63.0 million at the end of March 31, 2025.

“This FDA approval represents a historic milestone for Nyxoah and marks the beginning of what we expect to be a transformational period for our company,” commented Olivier Taelman, Nyxoah's Chief Executive Officer. “Genio is now the first and only bilateral hypoglossal neurostimulation therapy approved in the United States, offering a truly differentiated solution for OSA patients who have been underserved by existing therapies. Our world–class commercial team is in place, and we have begun to execute on our commercial strategy.”

FDA PMA Approval

As previously disclosed, on August 8, 2025, the Company received FDA PMA for its Genio system, marking a historic milestone for Nyxoah. Genio’s unique design utilizes bilateral stimulation, and offers patients a leadless, full–body 1.5T and 3T MRI compatible, non–implanted battery solution, powered and controlled by a wearable component.

The Genio system’s FDA approval was supported by the high–quality, differentiated safety and efficacy data from the Company's DREAM pivotal trial, which demonstrated that Genio is efficacious regardless of a patient's sleeping position. This is a critical differentiator as on average, people sleep in a supine position between 35% and 40% of the night. The DREAM study measured position–specific outcomes and demonstrated a 66.6% median AHI reduction while patients slept in a supine position despite the fact that the number of airway obstructions can double in this position. This reduction compares favorably to the 71.0% reduction in AHI shown while patients slept in a non–supine position.

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)
(in thousands)

      For the three months ended June 30   For the six months ended June 30  
      2025   2024   2025   2024
Revenue     1 340   771   2 404   1 992
Cost of goods sold     ( 490)   ( 281)   ( 896)   ( 735)
Gross profit     € 850   € 490   € 1 508   € 1 257
Research and Development Expense     (10 059)   (7 472)   (19 048)   (14 671)
Selling, General and Administrative Expense     (10 672)   (6 383)   (23 063)   (12 355)
Other income     31   58   115   249
Operating loss for the period     € (19 850)   € (13 307)   € (40 488)   € (25520)
Financial income     2 858   2 069   5 480   3 477
Financial expense     (3 337)   (1 445)   (7 579)   (2 436)
Loss for the period before taxes     € (20 329)   € (12 683)   € (42 587)   € (24479)
Income taxes     ( 278)   ( 441)   ( 404)   ( 551)
Loss for the period     € (20 607)   € (13 124)   € (42 991)   € (25030)
                   
Loss attributable to equity holders     € (20 607)   € (13 124)   € (42 991)   € (25030)
Other comprehensive loss                  
Items that may be subsequently reclassified to profit or loss (net of tax)                  
Currency translation differences     232   ( 82)   230   ( 22)
Total comprehensive loss for the year, net of tax     € (20 375)   € (13 206)   € (42 761)   € (25052)
Loss attributable to equity holders     € (20 375)   € (13 206)   € (42 761)   € (25052)
                   
Basic Loss Per Share (in EUR)     € (0.551)   € (0.428)   € (1.149)   € (0.843)
Diluted Loss Per Share (in EUR)     € (0.551)   € (0.428)   € (1.149)   € (0.843)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited)
(in thousands)

        As at
        June 30
2025		   December 31 2024
ASSETS            
Non–current assets            
Property, plant and equipment       5 015   4 753
Intangible assets       51 407   50 381
Right of use assets       3 059   3 496
Deferred tax asset       76   76
Other long–term receivables       1 799   1 617
        € 61 356   € 60 323
Current assets            
Inventory       5 332   4 716
Trade receivables       1 330   3 382
Contract assets       1 508   −
Other receivables       3 014   2 774
Other current assets       944   1 656
Financial assets       20 257   51 369
Cash and cash equivalents       22 729   34 186
        € 55 114   € 98 083
Total assets       € 116 470   € 158 406
             
EQUITY AND LIABILITIES            
Share capital and reserves            
Share capital       6 431   6 430
Share premium       314 388   314 345
Share based payment reserve       11 645   9 300
Other comprehensive income       1 144   914
Retained loss       (260 211)   (217 735)
Total equity attributable to shareholders       € 73 397   € 113 254
             
LIABILITIES            
Non–current liabilities            
Financial debt       18 928   18 725
Lease liability       2 157   2 562
Provisions       404   1 000
Deferred tax liability       34   19
Contract liability       225   472
Other liability       379   845
        € 22 127   € 23 623
Current liabilities            
Financial debt       246   248
Lease liability       1 071   1 118
Trade payables       9 408   9 505
Current tax liability       3 990   4 317
Contract liability       460   117
Other liability       5 771   6 224
        € 20 946   € 21 529
Total liabilities       € 43 073   € 45 152
Total equity and liabilities       € 116 470   € 158 406

Revenue
Revenue was €1.3 million for the second quarter ending June 30, 2025, compared to €0.8 million for the second quarter ending June 30, 2024, representing a 74% year over year increase.

Cost of Goods Sold
Cost of goods sold was €490,000 for the second quarter ending June 30, 2025, representing a gross profit of €0.9 million, or gross margin of 63.4%. This compares to cost of goods sold of €281,000 in the second quarter ending June 30, 2024, for a gross profit of €0.5 million, or gross margin of 63.6%.

Research and Development
For the second quarter ending June 30, 2025, research and development (“R&D”) expenses were €10.0 million, versus €7.5 million for the second quarter ending June 30, 2024. The increase in research and development expenses was primarily due to higher R&D activities offset by a decrease in clinical study expenses.

Selling, General and Administrative
For the second quarter ending June 30, 2025, selling, general and administrative expenses were €10.7 million, versus €6.4 million for the second quarter ending June 30, 2024. The increase in selling, general and administrative expenses was primarily due to an increase in costs to support the commercialization of Genio system, including the Company’s overall scale–up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval.

Operating Loss
Total operating loss for the second quarter ending June 30, 2025 was €19.9 million, versus €13.3 million in the second quarter 2024, respectively. This was driven by an increase in selling, general and administrative expenses to support commercialization of the Genio system, including the Company’s overall scale–up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval, and increased R&D activities offset by a decrease in clinical study expenses.

Cash Position
As of June 30, 2025, cash, cash equivalents and financial assets totaled €43.0 million, compared to €63.0 million at the end of March 31, 2025. The Company also has a term debt facility with €27.5 million of remaining availability which can be drawn down in two equal tranches subject to revenue and other financial milestones.

Second Quarter 2025
Nyxoah’s financial report for the second quarter of 2025, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Company management will host a conference call to discuss financial results on Monday, August 18, 2025, beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Events | Nyxoah Investors required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

For Media
In United States
FINN Partners – Glenn Silver
[email protected]

For Media
Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

International/Germany
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Attachment


GLOBENEWSWIRE (Distribution ID 1001123459)

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025

INFORMATIONS RÉGLEMENTÉES

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025
La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit

Mont–Saint–Guibert, Belgique – 18 août 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui ses résultats financiers et d’exploitation pour le deuxième trimestre 2025.

Temps forts financiers et d’exploitation

  • Obtention de l'autorisation préalable à la mise sur le marché (PMA) de la Food and Drug Administration (FDA) américaine pour le système Genio, la première et unique thérapie de neurostimulation hypoglosse bilatérale approuvée aux États–Unis.
  • Lancement commercial du système Genio aux États–Unis.
  • Publication des données de l'étude pivot DREAM dans le Journal of Clinical Sleep Medicine.
  • Le chiffre d'affaires du deuxième trimestre 2025 s'est élevé à 1,3 million d'euros, contre 0,8 million d'euros au deuxième trimestre 2024, soit une croissance de 74 % en glissement annuel.
  • La trésorerie, les équivalents de trésorerie et les actifs financiers s'élevaient à 43,0 millions d'euros au 30 juin 2025, contre 63,0 millions d'euros au 31 mars 2025.

” Cette autorisation de la FDA représente une étape historique pour Nyxoah et marque le début de ce que nous espérons être une période de transformation pour notre entreprise “, a commenté Olivier Taelman, CEO de Nyxoah. ” Genio est désormais le premier et le seul traitement par neurostimulation hypoglossale bilatérale approuvé aux États–Unis, offrant une solution véritablement différenciée aux patients atteints d'AOS qui ont été mal desservis par les traitements existants. Notre équipe commerciale de classe mondiale est en place et nous avons commencé à mettre en œuvre notre stratégie commerciale. “

Autorisation PMA de la FDA

Comme annoncé précédemment, le 8 août 2025, la société a obtenu l'autorisation PMA de la FDA pour son système Genio, marquant ainsi une étape historique pour Nyxoah. La conception unique de Genio utilise une stimulation bilatérale et offre aux patients une solution sans fil, compatible avec l'IRM 1,5 T et 3 T pour tout le corps, sans implant et alimentée par une batterie, contrôlée par un composant portable.

L'autorisation de la FDA pour le système Genio s'appuie sur les données de haute qualité, différenciées en termes de sécurité et d'efficacité, issues de l'essai pivot DREAM mené par la société, qui a démontré l'efficacité de Genio quelle que soit la position de sommeil du patient. Il s'agit là d'un facteur de différenciation essentiel, car en moyenne, les personnes dorment en position couchée sur le dos entre 35 % et 40 % de la nuit. L'étude DREAM a mesuré les résultats spécifiques à la position et a démontré une réduction médiane de 66,6 % de l'IAH lorsque les patients dormaient en position couchée sur le dos, malgré le fait que le nombre d'obstructions des voies respiratoires puisse doubler dans cette position. Cette réduction est comparable à la réduction de 71,0 % de l'IAH observée lorsque les patients dormaient dans une position autre que couchée sur le dos.

ÉTATS CONSOLIDÉS DES PERTES ET AUTRES ÉLÉMENTS DU RÉSULTAT GLOBAL (non audités)

(en milliers)

      Pour la période de trois mois clôturée le 30 juin   Pour la période de six mois clôturée le 30 juin
      2025   2024   2025   2024  
Chiffre d’affaires     € 1 340   € 771   € 2 404   € 1 992  
Coût des biens vendus     ( 490)   ( 281)   ( 896)   ( 735)  
Bénéfice brut     € 850   € 490   € 1 508   € 1 257  
Frais de recherche et de développement     (10 059)   (7 472)   (19 048)   (14 671)  
Frais de vente, dépenses administratives et autres frais généraux     (10 672)   (6 383)   (23 063)   (12 355)  
Autres revenus d’exploitation     31   58   115   249  
Perte d’exploitation de la période     € (19 850)   € (13 307)   € (40 488)   € (25 520)  
Produits financiers     2 858   2 069   5 480   3 477  
Charges financières     (3 337)   (1 445)   (7 579)   (2 436)  
Perte de la période avant impôts     € (20 329)   € (12 683)   € (42 587)   € (24 479)  
Impôts sur le revenu     ( 278)   ( 441)   ( 404)   ( 551)  
Perte de la période     € (20 607)   € (13 124)   € (42 991)   € (25 030)  
                     
Perte attribuable aux actionnaires     € (20 607)   € (13 124)   € (42 991)   € (25 030)  
Autres éléments du résultat global                    
Eléments pouvant être reclassifiés en bénéfices ou en pertes (nets d’impôts)                    
Différences de conversion de devises     232   ( 82)   230   ( 22)  
Perte globale totale de la période, nette d’impôts     € (20 375)   € (13 206)   € (42 761)   € (25 052)  
Perte attribuable aux actionnaires     € (20 375)   € (13 206)   € (42 761)   € (25 052)  
                     
Perte par action (en €)     € (0,551)   € (0,428)   € (1,149)   € (0,843)  
Perte diluée par action (en €)     € (0,551)   € (0,428)   € (1,149)   € (0,843)  

ÉTAT CONSOLIDÉ DE LA SITUATION FINANCIÈRE (non audité)
(en milliers)

      Au
      30 juin
2025 		  31 décembre
2024
ACTIFS          
Actifs non courants          
Immobilisations corporelles     5 015   4 753
Immobilisations incorporelles     51 407   50 381
Droit d’utilisation des actifs     3 059   3 496
Actif d’impôts différés     76   76
Autres créances à long terme     1 799   1 617
      €61356   € 60 323
Actifs courants          
Stocks     5 332   4 716
Créances commerciales     1 330   3 382
Actifs liés à des contrats     1 508   −
Autres créances     3 014   2 774
Autres actifs courants     944   1 656
Actifs financiers     20 257   51 369
Trésorerie et équivalents de trésorerie     22 729   34 186
      € 55114   € 98 083
Total de l’actif     € 116470   € 158 406
           
CAPITAUX PROPRES ET PASSIFS          
Capital et réserves          
Capital     6 431   6 430
Prime d’émission     314 388   314 345
Réserve pour paiement fondé sur des actions     11 645   9 300
Autres éléments du résultat global     1 144   914
Résultats reportés     (260211)   (217 735)
Total des capitaux propres attribuables aux actionnaires     € 73397   € 113 254
           
PASSIFS          
Passifs non courants          
Dettes financières     18 928   18 725
Passifs locatifs     2 157   2 562
Provisions     404   1 000
Passif d’impôts différés     34   19
Responsabilité contractuelle     225   472
Autres passifs     379   845
      € 22 127   € 23 623
Passifs courants          
Dettes financières     246   248
Passifs locatifs     1 071   1 118
Dettes commerciales     9 408   9 505
Passif d’impôts exigibles     3 990   4 317
Responsabilité contractuelle     460   117
Autres passifs     5 771   6 224
      € 20 946   € 21 529
Total du passif     € 43 073   € 45 152
Total des capitaux propres et du passif     € 116470   € 158 406

Revenus

Le chiffre d'affaires s'est élevé à 1,3 million d'euros pour le deuxième trimestre clos le 30 juin 2025, contre 0,8 million d'euros pour le deuxième trimestre clos le 30 juin 2024, soit une augmentation de 74 % en variation annuelle.

Coût des marchandises vendues
Le coût des marchandises vendues s'est élevé à 490 000 € pour le deuxième trimestre clos le 30 juin 2025, ce qui représente un bénéfice brut de 0,9 million d'euros, soit une marge brute de 63,4 %. Ce chiffre est à comparer au coût des marchandises vendues de 281 000 € au deuxième trimestre clos le 30 juin 2024, pour une marge brute de 0,5 million d'euros, soit une marge brute de 63,6 %.

Recherche et développement
Pour le deuxième trimestre clos le 30 juin 2025, les dépenses de recherche et développement (« R&D ») se sont élevées à 10,0 millions d'euros, contre 7,5 millions d'euros pour le deuxième trimestre clos le 30 juin 2024. L'augmentation des dépenses de recherche et développement est principalement due à l'intensification des activités de R&D, compensée par une diminution des dépenses liées aux études cliniques.

Frais commerciaux, généraux et administratifs
Pour le deuxième trimestre clos le 30 juin 2025, les frais commerciaux, généraux et administratifs se sont élevés à 10,7 millions d'euros, contre 6,4 millions d'euros pour le deuxième trimestre clos le 30 juin 2024. L'augmentation des frais de vente, généraux et administratifs est principalement due à une hausse des coûts liés à la commercialisation du système Genio, notamment les préparatifs généraux de la société en vue de la commercialisation du système Genio aux États–Unis dans le cadre de l'obtention de l'autorisation de la FDA.

Perte d'exploitation
La perte d'exploitation totale pour le deuxième trimestre clos le 30 juin 2025 s'est élevée à 19,9 millions d'euros, contre 13,3 millions d'euros au deuxième trimestre 2024. Cette augmentation s'explique par la hausse des frais commerciaux, généraux et administratifs liés à la commercialisation du système Genio, notamment les préparatifs généraux de la société en vue de la commercialisation du système Genio aux États–Unis suite à l'obtention de l'autorisation de la FDA, ainsi que par l'intensification des activités de R&D, compensées par une baisse des dépenses liées aux études cliniques.

Position de trésorerie
Au 30 juin 2025, la trésorerie et les actifs financiers s'élevaient à 43,0 millions d'euros, contre 63,0 millions d'euros au 31 mars 2025. La Société dispose également d'une facilité de crédit à terme d'un montant restant disponible de 27,5 millions d'euros, qui peut être utilisée en deux tranches égales sous réserve de la réalisation d'objectifs en matière de chiffre d'affaires et d'autres objectifs financiers.

Deuxième Trimestre 2025

Le rapport financier de Nyxoah pour le deuxième trimestre 2025, y compris les détails des résultats consolidés audités, sont disponibles sur la page investisseurs du site web de Nyxoah (https://investors.nyxoah.com/financials).

Conférence téléphonique et webcast

Le management de la Société organisera une conférence téléphonique pour discuter ses résultats financiers le lundi 18 août 2025, à 22h30 CET / 16h30 ET.

La retransmission de la conférence téléphonique sera accessible sur la page Investor Relations du site web de Nyxoah ou par le biais de ce lien : Nyxoah's Q2 2025 Earnings Call Webcast. Pour ceux qui n'ont pas l'intention de poser une question au Management, la Société recommande d'écouter la webdiffusion.

Si vous avez l'intention de poser une question, veuillez utiliser le lien suivant : Nyxoah's Q2 2025 Earnings Call. Après l'inscription, un courriel sera envoyé, comprenant les détails de la connexion et un code d'accès unique à la conférence téléphonique nécessaire pour rejoindre l'appel en direct. Pour s'assurer que vous êtes connecté avant le début de la conférence, la Société suggère de s'inscrire au moins 10 minutes avant le début de l'appel.

Le webcast archivé pourra être réécouté peu après la clôture de la conférence.

A propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la Food and Drug Administration (FDA) américaine pour un sous–groupe de patients atteints d'AOS modérée à sévère avec un indice d'apnée–hypopnée (IAH) supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur ordonnance.

Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Medias

Aux États–Unis
FINN Partners – Alyssa Paldo
[email protected]

International / Allemagne
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Belgique / France
Backstage Communication – Gunther De Backer
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001123459)

24/7 concierge: Zoom’s agentic AI and virtual agent now extends to Zoom Phone, helping businesses capture more calls and opportunities

  • Zoom Virtual Agent expands to Zoom Phone, enabling a new concierge use case that delivers personalized support with agentic concierge capabilities to automate routine calls and streamline frontline service across departments
  • Zoom AI Companion enhances agentic scheduling to coordinate meetings end–to–end, finding the best time, contacting attendees, tracking responses, and recommending next steps without the back–and–forth
  • Zoom Hub launches, providing a centralized workspace to create, find, and manage Zoom files
  • Zoom Team Chat adds AI Companion to mobile for easier catch–up, and quick document summaries without needing to open the file in the Zoom Workplace desktop app, saving time and boosting productivity

SAN JOSE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced a new concierge use case for Zoom Virtual Agent, now integrated with Zoom Phone, giving businesses a smarter way to answer calls and better support callers from the start. Zoom also announced the launch of Zoom Hub, a centralized content center to help users organize, manage, and create Zoom assets, and enhanced AI features across Zoom Meetings and Team Chat to help teams work faster and stay aligned in real time.

A 24/7 AI receptionist that does more than route calls

Zoom Virtual Agent, now integrated with Zoom Phone, provides an elevated concierge experience that goes beyond basic call answering services or auto–attendants. As your newest front desk team member, the concierge greets callers, speaks naturally, processes input, and initiates the most appropriate next step. From booking appointments to providing updates and routing to the right person without phone trees or long hold times, it helps organizations reduce missed calls and deliver a more professional first impression.

“When someone calls your business, it should feel easy and personal from the first hello. By combining AI that can listen, understand, and take action with the reach of Zoom Phone, our concierge virtual agent provides seamless and personalized support to all callers,” said Smita Hashim, chief product officer at Zoom. “Whether a customer is calling to schedule an appointment, check an order status, or check product availability, Zoom’s concierge is available 24×7 and can deliver answers instantly, escalating to live employees only when needed. The result is a faster, more personalized, and more scalable experience for everyone.”

Admins can save time and avoid tech headaches by easily deploying the concierge within minutes using a no–code configuration. By uploading documents or pointing to a website, teams can quickly train the concierge to greet callers and respond to real–world questions. Built to work with diverse audiences, it supports natural, multilingual conversations in English, Spanish, French, German, Portuguese, and Japanese, with more on the way, and is available 24/7 so callers get a fast, consistent experience any time of the day.

Zoom Virtual Agent (ZVA) concierge supports a wide range of use cases, including:

  • Healthcare: In fast–paced care settings, ZVA concierge can help patients get connected with the care they need quickly. It can route calls to the right department, answer common questions like “Are you accepting new patients?”, and let patients book appointments by phone, even after hours, freeing staff to focus on care delivery.
  • Retail: When customers call with specific needs like finding the right product for a project or checking if an item is in stock, ZVA concierge can answer their questions, confirm if an item is in stock (even down to the aisle), schedule pickup, and more, all without requiring human assistance.
  • Manufacturing: For companies juggling service requests and product support, ZVA concierge can capture customer requests, guide them through troubleshooting over the phone, and direct them to the right team, day or night, without manual intake.
  • Financial services: Personalized service is critical in financial conversations. ZVA concierge can greet clients, gather information about why they’re calling, and resolve the request on the spot, like providing application updates, or connect them to the right advisor with all the details already captured, reducing wait times while providing a high–touch experience.

The Zoom Virtual Agent phone concierge capability is available today. To learn more or request a demo, visit zoom.com.

Agentic meeting scheduling without the back and forth

The AI Companion meeting scheduling skill uses agentic AI to eliminate the friction of finding a time that works for everyone, whether scheduling with colleagues or external partners. Instead of juggling calendars, tracking multiple time zones, and managing out–of–office notices, AI Companion instantly analyzes all of these factors to surface the most convenient options.

Once a preferred time is selected, AI Companion takes over the coordination process, reaches out to invitees directly, sends meeting requests, and keeps a real–time pulse on responses, whether via email or Zoom Team Chat. If a proposed time no longer works, it immediately suggests an alternative, ensuring the conversation keeps moving and the meeting is confirmed quickly.

This end–to–end automation prevents scheduling delays and missed opportunities. AI Companion acts as a dedicated meeting coordinator, removing tedious back–and–forth, reducing scheduling errors, and giving teams more time to focus on the discussion itself, not the logistics.

A new asset hub to stay organized and work efficiently

Zoom Hub, now generally available, introduces a streamlined way for users to stay organized and take action across Zoom Workplace. As a central destination within Zoom Workplace, Zoom Hub works with AI Companion to help users create content more efficiently, while also bringing together Zoom meeting recordings, meeting summaries, docs, whiteboards, clips, and more, eliminating the need to jump between tools or hunt for files.

  • Stay organized, with the ability to view your Zoom assets in one place and organize assets by folder.
  • Catch up and prepare for meetings easily by searching for files by meeting.
  • Kickstart drafts with AI Companion in Zoom Hub, including Zoom docs or data tables, whiteboards, and clips.

A chat experience that works smarter with AI

Zoom Team Chat users can now work smarter on the go with AI Companion built right into the Team Chat compose bar and a refreshed mobile experience, making it easier to draft messages and catch up on unread messages. When using Team Chat in the Zoom Workplace desktop app, users can now see a summary of a document by selecting the summarize icon when hovering over the file card without having to open the file, helping save more time.

Additionally, to help improve AI Companion’s ability to handle agentic tasks like meeting scheduling and translating conversations into actionable outcomes for users, Zoom will be among the first to integrate OpenAI’s GPT–5 into its AI stack.

Zoom AI Companion’s new agentic capabilities and enhancements help users save time in the workday and are included at no additional cost with paid Zoom Workplace plans. These updates reinforce Zoom’s commitment to building a truly AI–first collaboration platform that helps teams work faster, stay aligned, and focus on what matters most.

To learn more about Zoom Workplace, visit the Zoom website.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations
Travis Isaman
[email protected]


GLOBENEWSWIRE (Distribution ID 9514089)

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

                                      

Extrovis AG
Bahnhof Park 4
6340, Baar, Switzerland		 Media Relations Contact
Madhu Marur
[email protected]

                                        

Press Release

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Baar, Switzerland; August 14, 2025

Extrovis AG, a global pharmaceutical company focused on research–driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).

Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

“This product generic launch marks a key milestone in our commitment to increasing patient access and long–term value creation for the U.S. healthcare system. Our partnership with Dr. Reddy’s helps ensure that patients and healthcare providers in the United States have continued access to a high–quality and cost–effective product,” said Hans R. Kamma Co–CEO and Chief Strategy Officer of Extrovis AG.

“Dr. Reddy’s brings deep expertise in commercialization and distribution within the U.S. market,” added Raghavendra Rao PV, Chief Financial Officer of Extrovis AG. “This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly.”

The partnership reinforces Extrovis’ strategy to extend the reach of its therapeutics while advancing long–term affordability and sustainability in healthcare.

Dr. Reddy’s Fluorouracil Cream, 0.5%, is supplied in a 30–gram tube for topical use only. Please click here to see the full prescribing information.

                                                                                     

Carac® is a trademark of Extrovis AG

……………………………………………………………………………………..……………………………………………………………………………………………………………………

About Dr. Reddy’s
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

About Extrovis AG
Extrovis AG is a Switzerland–based global biopharmaceutical company committed to developing and commercializing high–quality therapies for unmet and under–addressed medical needs. With R&D and manufacturing operations in the USA, Italy, Hungary, and India, Extrovis delivers innovative, differentiated products across key therapeutic areas. Backed by strong R&D capabilities, regulatory expertise, and a robust global quality framework, the company advances its mission to improve patient outcomes and expand access to essential health care products worldwide. For more information, log on to: http://www.extrovis.com

………………………………………………………………………………………………………………………………………………………

Disclaimer: This press release may include statements of future expectations and other forward–looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward–looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward–looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID–19). The company assumes no obligation to update any information contained herein.

 

Attachment


GLOBENEWSWIRE (Distribution ID 1001123392)

BTCS Offers Shareholders a $0.05 per share “Bividend” – a Blockchain Dividend Payable in Ethereum

SILVER SPRING, MD, Aug. 18, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology–focused company, short for Blockchain Technology Consensus Solutions, today announced that it is paying shareholders a one–time blockchain dividend, or “Bividend” of $0.05 per share in Ethereum (ETH). The Bividend marks the first time a public company has paid a dividend in ETH.

BTCS is also offering a one–time $0.35 per share loyalty payment, payable solely in ETH, to shareholders who move their shares to book entry with the Company’s transfer agent and keep them there for at least 120 days, which should reduce the ability of shares to be lent for short–selling purposes. Together, the Bividend and loyalty payment total $0.40 per share in ETH for eligible shareholders. Officers, directors, and employees of the Company, as well as Series V Preferred holders, are not eligible for the $0.35 per share loyalty payment.

“We are paying the Bividend and loyalty payment to thank our long–term shareholders and empower them to take control of and protect their investment,” said Charles Allen, CEO of BTCS. “By moving to book entry, our shareholders receive a tangible benefit and prevent their shares from being lent to short sellers, protecting against market manipulation and forcing institutional short sellers to either cover or call in existing short positions.”

“Right now, short sellers are betting against BTCS because they expect us to sell a significant number of shares to raise capital,” said Allen. “As the largest shareholder of BTCS, let me be perfectly clear: my goal is to grow our market cap primarily through share price appreciation, not toxic dilution. I have and will continue to aggressively protect our company and our shareholders from institutions that short our stock to profit at your expense.”

BTCS intends to pay the $0.05 per share ETH Bividend based on ETH’s price on the record date. Investors who do not elect to receive the ETH Bividend will receive a cash dividend of $0.05 per share.

As of August 15, 2025, BTCS stock closed at $4.41 per share, despite holding approximately $6.65 per share in cash and digital assets, illustrating the compelling value proposition for our shareholders. This underscores the disconnect between our share price and the intrinsic value of our underlying assets and operating business, making it an appropriate time to reward shareholders with this distribution.

Shareholders should consult their tax advisors regarding the tax implications of receiving this distribution and the loyalty payment.

“We have a history of rewarding our shareholders for their loyalty: in addition to paying a Bividend in Bitcoin in 2022, we are the first public company in the world to pay a Bividend in Ethereum,” said Allen. “This is a moment we have long anticipated since our February 2015 purchase of bividend.com.”

How can shareholders participate in the Bividend?

To receive the Bividend in ETH, prior to the record date, BTCS shareholders must: (1) complete the opt–in form available through bividend.com, and (2) transfer their shares to our transfer agent, Equity Stock Transfer, by following the provided instructions. Any shareholder who does not opt–in to receive their Ethereum Bividend will automatically receive the dividend in USD.

BTCS has set a record date of September 26, 2025, allowing ample time for shareholders to complete the opt–in process and move their shares before the record date.

The Bividend, and the equivalent cash dividend, will be paid as soon as possible after the record date.

How can shareholders receive the loyalty payment?

In addition to the Bividend, BTCS will issue a one–time loyalty payment of $0.35 per share to Common Stock shareholders who hold their shares with the Company’s transfer agent from September 26, 2025, through January 26, 2026. Shareholders need to complete the opt–in form and transfer their shares to our transfer agent, Equity Stock Transfer, to receive the loyalty payment.

Payable solely in ETH, the loyalty payment is designed to reward long–term shareholders who demonstrate continued support for BTCS’s vision and strategy and potentially limit predatory short–selling practices.

The loyalty payment will be paid as soon as possible after January 26, 2026.

Full details are outlined on bividend.com and disclosed in a Form 8–K filed with the Securities and Exchange Commission on August 18, 2025. Series V Preferred shareholders will also receive a $0.05 cash dividend and are not eligible for the loyalty payment.

CEO Charles Allen recently published a thought leadership piece entitled “Why Fake Shares and Forced Lending Must Be Outlawed” that can be found here.

About BTCS:
BTCS Inc. (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, is a U.S.–based Ethereum–first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance (“DeFi”) and traditional finance (“TradFi”) mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield–focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.

Cautionary Note Regarding Forward–Looking Statements
Certain statements in this press release constitute “forward–looking statements” within Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 including statements regarding our ability to successfully implement and pay the Bividend and loyalty payment, growth in our market cap and appreciation in stock price. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward–looking statements. While the Company believes these forward–looking statements are reasonable, undue reliance should not be placed on any such forward–looking statements, which are based on information available to us on the date of this release. These forward–looking statements are based upon assumptions and are subject to various risks and uncertainties, regulatory issues, unanticipated issues on Nasdaq with respect to implementing the Bividend or issues implementing the loyalty payment, as well as risks set forth in the Company’s filings with the Securities and Exchange Commission including its Form 10–K for the year ended December 31, 2024 which was filed on March 20, 2025. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements, whether as a result of new information, future events or otherwise, except as required by law.

For more information follow us on:
X: https://x.com/NasdaqBTCS
LinkedIn: https://www.linkedin.com/company/nasdaq–btcs
Facebook: https://www.facebook.com/NasdaqBTCS

Investor Relations:
Charles Allen – CEO
X: @Charles_BTCS
Email: [email protected]


GLOBENEWSWIRE (Distribution ID 9513644)

Lantronix-Lösung unterstützt die von der US-Armee zugelassenen Teal Drones, ein Unternehmen der Red Cat Holdings, und erschließt Wachstumschancen für sichere Edge-KI

IRVINE, Kalifornien, Aug. 18, 2025 (GLOBE NEWSWIRE) — Lantronix Inc.– (NASDAQ: LTRX), ein weltweit führender Anbieter von IoT–Lösungen für Computer und Konnektivität, die Edge–KI–Anwendungen unterstützen, gab heute bekannt, dass seine TAA– und NDAA–konforme Lösung von Teal Drones, einem Unternehmen von Red Cat Holdings Inc. (NASDAQ: RCAT), für die Produktion seiner Black–Widow™–Drohnen im Rahmen des Short–Range–Reconnaissance–(SRR)–Programms der US–Armee ausgewählt wurde. Lantronix hat bereits mit der Produktion begonnen, was frühzeitige Umsatztransparenz ermöglicht und die Rolle von Lantronix als vertrauenswürdiger Technologiepartner für unternehmenskritische Verteidigungsanwendungen unterstreicht.

Die auf dem Prozessor Qualcomm® Dragonwing™ QRB5165 basierende Lantronix–Lösung bietet fortschrittliche Edge–KI–Verarbeitung und erfüllt gleichzeitig die strengen Sicherheitsanforderungen der USA. Sie ermöglicht die vollständige TAA– und NDAA–Konformität für den Einsatz in sensiblen Missionen des Verteidigungsministeriums. Die Kombination aus KI–Leistung und Compliance verschafft Lantronix einen nachhaltigen Vorteil auf dem schnell wachsenden Markt für Verteidigungs– und autonome Systeme.

Als Teil einer ausgewählten Gruppe von kleinen, von Blue UAS zugelassenen Anbietern unbemannter Luftsysteme müssen Teal Drones für den Einsatz durch das US–Verteidigungsministerium strenge Cybersicherheits–, Betriebs– und Sicherheitsstandards erfüllen. Die konforme Lösung von Lantronix ermöglicht es Teal, diese Anforderungen zu erfüllen und seine Black–Widow–Drohnen für den Einsatz in Frontmissionen zu positionieren.

„Black–Widow–Drohnen definieren die Möglichkeiten kleiner unbemannter Systeme neu und bieten den heutigen Soldaten Echtzeitinformationen und den operativen Vorsprung, den sie auf dem modernen Schlachtfeld brauchen“, sagt Jeff Thompson, CEO von Red Cat. „Die Lösung von Lantronix ermöglicht es uns, die strengen TAA– und NDAA–Konformitätsstandards der US–Armee im Rahmen des SRR–Programms zu erfüllen – ein Maß an Sicherheit, das nur wenige Anbieter bieten können.“

Der globale Drohnenmarkt soll bis 2030 voraussichtlich 57,8 Milliarden US–Dollar erreichen (Global Drone Market Report 2025–2030 von Drone Industry Insights). Die Präsenz von Lantronix im Segment der sicheren Verteidigungs– und kommerziellen Drohnen schafft mehrjährige Wachstumschancen mit hohen Margen.

—–„Lantronix hat sich als führendes Unternehmen im Edge–KI–Markt etabliert und bietet innovative, Compliance–orientierte Lösungen für den wachsenden Drohnensektor“, sagt Saleel Awsare, CEO und Präsident von Lantronix. „Unsere Zusammenarbeit mit Teal Drones unterstreicht unsere Fähigkeit, sichere, leistungsstarke Produkte in großem Maßstab auf den Markt zu bringen und so langfristige Chancen mit führenden globalen Marken zu schaffen.“

—Die Lösungen und Engineering Services von Lantronix kombinieren eingebettete Computertechnologie, Compliance–Expertise und flexiblen Software–Support, um die Produktentwicklung der Kunden zu beschleunigen. Dieser skalierbare Plattformansatz ermöglicht nicht nur eine schnelleMarkteinführung von Teal Drones, sondern versetzt Lantronix auch in die Lage, zukünftige Verteidigungs– und industrielle IoT–Programme zu unterstützen, die TAA– und NDAA–Konformität erfordern.

Weitere Informationen zu den Engineering Services, SOM–Lösungen und zusätzlichen Drohnenanwendungen von Lantronix finden Sie auf Lantronix.com.

Über Lantronix   

Lantronix Inc. (Nasdaq: LTRX) ist ein weltweit führender Anbieter von Edge–KI– und industriellen IoT–Lösungen und bietet intelligentes Computing, sichere Konnektivität sowie Remote–Management für unternehmenskritische Anwendungen. Lantronix bedient wachstumsstarke Märkte, darunter Smart Cities, Unternehmens–IT sowie unbemannte kommerzielle und militärische Systeme, und ermöglicht seinen Kunden, ihre Betriebsabläufe zu optimieren sowie die digitale Transformation zu beschleunigen. Sein umfassendes Portfolio an Hardware, Software und Diensten unterstützt Anwendungen von sicherer Videoüberwachung und intelligenter Versorgungsinfrastruktur bis hin zu robustem Out–of–Band–Netzwerkmanagement. Indem Lantronix Intelligenz an den Netzwerkrand bringt, hilft es Unternehmen, in der heutigen KI–gesteuerten Welt Effizienz, Sicherheit und einen Wettbewerbsvorteil zu erreichen.

Weitere Informationen finden Sie auf der Website von Lantronix.

Über Red Cat Holdings Inc.

Red Cat (Nasdaq: RCAT) ist ein in den USA ansässiger Anbieter fortschrittlicher Drohnen– und Roboterlösungen für alle Bereiche der Verteidigung und nationalen Sicherheit. Über seine hundertprozentigen Tochtergesellschaften Teal Drones und FlightWave Aerospace entwickelt Red Cat in den USA hergestellte Hardware und Software, die Militär–, Regierungs– und öffentliche Sicherheitsoperationen in der Luft, zu Land und zur See unterstützt. Seine Systemfamilie, angeführt von Black Widow™, bietet unübertroffene taktische Fähigkeiten in kleinen unbemannten Flugzeugsystemen. Red Cat expandiert über Blue OPS, Inc. in den maritimen Bereich und entwickelt außerdem Innovationen im Bereich unbemannter Überwasserschiffe und autonomer Unterwasserfahrzeuge. Das Unternehmen liefert integrierte Plattformen zur Verbesserung der Sicherheit und Effektivität von Missionen in mehreren Bereichen. Weitere Informationen finden Sie unter www.redcat.red.

©2025 Lantronix, Inc. Alle Rechte vorbehalten. Lantronix ist eine eingetragene Marke. Andere Marken und Markennamen sind Eigentum der jeweiligen Inhaber.

„Safe Harbor“–Erklärung gemäß dem Private Securities Litigation Reform Act von 1995: Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne der US–Bundeswertpapiergesetze, insbesondere Aussagen in Bezug auf Produkte oder die Geschäftsführung von Lantronix.  Diese zukunftsgerichteten Aussagen basieren auf unseren aktuellen Erwartungen und unterliegen erheblichen Risiken und Ungewissheiten, die dazu führen können, dass unsere tatsächlichen Ergebnisse, zukünftigen Geschäfts–, Finanz– oder Leistungsergebnisse erheblich von unseren historischen Ergebnissen oder von denen, die in den zukunftsgerichteten Aussagen in dieser Pressemitteilung ausgedrückt oder impliziert werden, abweichen. Zu den potenziellen Risiken und Ungewissheiten gehören unter anderem Faktoren wie die Auswirkungen negativer oder sich verschlechternder regionaler und weltweiter wirtschaftlicher Bedingungen oder Marktinstabilität auf unser Geschäft, einschließlich der Auswirkungen auf die Kaufentscheidungen unserer Kunden; unsere Fähigkeit, Unterbrechungen in unseren Lieferketten und denen unserer Zulieferer und Verkäufer aufgrund der COVID–19–Pandemie oder anderer Ausbrüche, Kriege und jüngster Spannungen in Europa, Asien und dem Nahen Osten oder anderer Faktoren abzumildern; künftige Reaktionen auf und Auswirkungen von Krisen im Bereich der öffentlichen Gesundheit; Risiken im Bereich der Cybersicherheit; Änderungen geltender US–amerikanischer und ausländischer Cybersicherheitsrisiken; Änderungen der geltenden Gesetze, Vorschriften und Zölle der US–amerikanischen und ausländischer Regierungen; unsere Fähigkeit, unsere Übernahmestrategie erfolgreich umzusetzen oder erworbene Unternehmen zu integrieren; Schwierigkeiten und Kosten des Schutzes von Patenten und anderen Eigentumsrechten; die Höhe unserer Verschuldung, unsere Fähigkeit, unsere Verschuldung zu bedienen, und die Beschränkungen in unseren Schuldverträgen; sowie alle weiteren Faktoren, die in unserem Jahresbericht auf Formblatt 10–K für das am 30. Juni 2024 zu Ende gegangene Geschäftsjahr enthalten sind, der am 9. September 2024 bei der US–amerikanischen Börsenaufsichtsbehörde (der „SEC“) eingereicht wurde, einschließlich des Abschnitts „Risikofaktoren“ in Punkt 1A von Teil I dieses Berichts, sowie in unseren anderen öffentlichen Einreichungen bei der SEC.  Weitere Risikofaktoren können von Zeit zu Zeit in unseren zukünftigen Veröffentlichungen genannt werden. Darüber hinaus können die tatsächlichen Ergebnisse aufgrund zusätzlicher Risiken und Unsicherheiten, die wir derzeit nicht kennen oder die wir derzeit nicht als wesentlich für unser Geschäft einschätzen, abweichen. Aus diesen Gründen sind die Anleger dazu angehalten, zukunftsgerichtete Aussagen mit der gebotenen Vorsicht zur Kenntnis zu nehmen. Die in dieser Mitteilung enthaltenen zukunftsgerichteten Aussagen beziehen sich ausschließlich auf den Zeitpunkt ihrer Veröffentlichung. Wir lehnen ausdrücklich jede Absicht oder Verpflichtung ab, zukunftsgerichtete Aussagen nach diesem Datum zu aktualisieren, es sei denn, dies ist gesetzlich vorgeschrieben oder durch die Regeln der Nasdaq Stock Market LLC festgelegt. Wenn wir zukunftsgerichtete Aussagen aktualisieren oder korrigieren, sollten Anleger nicht davon ausgehen, dass wir weitere Aktualisierungen oder Korrekturen vornehmen werden.

Lantronix–Medienkontakt:         
[email protected]
949–212–0960 

Lantronix – Analysten– und Anlegerkontakt:         
[email protected]


GLOBENEWSWIRE (Distribution ID 9513766)